IP Library Granted Patent US 8,980,821
Granted Patent B2
US 8,980,821 · App. 13/088,233 · Granted Mar 17, 2015

Treatment with a pharmaceutical composition comprising MANF2 necleic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,980,821
App. No.
13/088,233
Granted
Mar 17, 2015
Kind
B2
Abstract

A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.

Claims (4)

1. A method of treating the symptoms of Parkinson's disease in a patient in need thereof, the method comprising:

directly administering to the central nervous system of the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof, wherein said functional fragment is capable of preventing the 6-hydroxydopamine (6-OHDA)-induced degeneration of dopaminergic neurons, and wherein said functional fragment comprises amino acids 27-187 of the amino acid sequence of SEQ ID NO:2.

2. The method of claim 1 wherein the pharmaceutical composition comprises SEQ. ID NO:2.

3. The method of claim 1 , wherein the functional fragment consists of amino acids 27-187 of the amino acid sequence of SEQ ID NO:2.

Assignments (1)
CHANGE OF NAME Recorded Oct 14, 2014
From: HERMO PHARMA LTD.
To: HERANTIS PHARMA OYJ
Reel/Frame 033987/0452 →